Human Amniotic Membrane

Phase 2Biologic

UUniversity of Utah

Human Amniotic Membrane is one of 6 biologic programs targeting Osteonecrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteonecrosisRecruiting

OsteonecrosisPhase 2

Recruiting

Competition

Competitive Landscape

6 competitors in Osteonecrosis

#DrugCompanyPhaseTrials

Fosamax

OOrganon and Co

Approved

2 2

Trental

VValidus Pharmaceuticals

Phase 3

1 3

Tocopherol

MM.D. Anderson Cancer Center

Phase 3

1 4

Human Amniotic Membrane

UUniversity of Utah

Phase 2

1 5

Mononuclear Cells

NNational University of Malaysia

Preclinical

1 6

Platelets

LLeiden University Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atrial Fibrillation1 trial

Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation

Completed·UUniversity of Utah·Phase 1·NCT04130061·27 enrolled

Osteonecrosis1 trial

Human Amniotic Membrane (hAM) for Stage II Maxillomandibular Osteonecrosis Management

Recruiting·—·Phase 2·NCT05664815·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Human Amniotic Membrane. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Human Amniotic Membrane compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Human Amniotic Membrane. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Utah company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Utah

Human Amniotic Membrane

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atrial Fibrillation1 trial

Osteonecrosis1 trial

References

Drug Info

Quick Facts

Related News